Purpose of Review
This paper aims to provide a summary of the recent therapeutic advances and the latest research on outcome measures for clinical trials in juvenile dermatomyositis (JDM).
Recent randomized controlled trials (RCTs) have demonstrated the superiority of the combination of prednisone with methotrexate over other conventional therapies and the potential effectiveness of rituximab in refractory cases. A multinational project has led to develop new criteria for the definition of minimal, moderate, and major improvement in future JDM clinical trials. This effort has been paralleled by the establishment of criteria for clinically inactive disease. The validation of the first composite disease activity score for JDM is in progress.
The new outcome measures will increase the reliability of assessment of clinical response in JDM clinical trials and foster future multinational RCTs aimed to investigate novel treatment strategies for refractory forms of JDM.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371:2201–12.
Rider LG, Lidsley CB, Millwe FW. Juvenile dermatomyositis. In: Petty RE, Laxer RM, Lindsey CB, Wedderburn LR, editors. Textbook of pediatric rheumatology. 7th ed. Philadelphia: Elsevier Saunder; 2016. p. 351–84.
Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. For the NIAMS juvenile DM registry physician referral group. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases registry. Arthritis Rheum. 2003;49:300–5.
Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34:732–6.
Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res. 2010;62:63–72.
Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, et al. IMACS group. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009;60:3425–35.
Tollisen A, Sanner H, Flatø B, Wahl AK. Quality of life in adults with juvenile-onset dermatomyositis: a case-control study. Arthritis Care Res (Hoboken). 2012;64:1020–7.
Sanner H, Kirkhus E, Merckoll E, Tollisen A, Røisland M, Lie BA, et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: a case-control study. Arthritis Care Res (Hoboken). 2010;62:1103–11.
Ruperto N, Pistorio A, Ravelli A, Rider LG, Pilkington C, Oliveira S, et al. Paediatric rheumatology international trials organisation (PRINTO); pediatric rheumatology collaborative study group (PRCSG). The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62:1533–41.
Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N, et al. Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol. 2011;29:117–24.
Hasija R, Pistorio A, Ravelli A, Demirkaya E, Khubchandani R, Guseinova D, et al. Pediatric rheumatology international trials organization. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum. 2011;63:3142–52.
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. RIM study group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–24.
•• Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387:671–8. A randomized controlled trial showing the superiority of prednisone plus methotrexate over prednisone alone or prednisone plus cyclosporine.
Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a children’s arthritis and rheumatology research alliance consensus conference. Arthritis Care Res (Hoboken). 2010;62:219–25.
Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, et al. Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second childhood arthritis and rheumatology research alliance consensus conference. Arthritis Care Res (Hoboken). 2012;64:546–53.
• Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SJ, et al. Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash. J Rheumatol. 2017;44:110–6. This study presents consensus clinical treatment plans (CTP) for patients with JDM with persistent skin rash despite complete resolution of muscle disease developed by the Childhood Arthritis and Rheumatology Research Alliance.
• Kim S, Kahn P, Robinson AB, Lang B, Shulman A, Oberle EJ, et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J. 2017;15:1. Another proposal of consensus clinical treatment plans for children with JDM who have active skin rashes without significant muscle involvement made by the Childhood Arthritis and Rheumatology Research Alliance (CARRA).
•• Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76:329–40. This paper reports the evidence-based recommendations for the diagnosis and treatment of JDM developed in the context of a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE).
• McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, et al. Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Ann Rheum Dis. 2018;77(2):241–250. This study introduces an internationally agreed dataset for JDM that is designed to capture disease activity and damage over time and is aimed to enhance collaborative research and allow integration of data between centers.
Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al. International myositis assessment and clinical studies group. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52:2607–15.
Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001;40:1262–73.
Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol. 2003;30:603–17.
Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford). 2003;42:1452–9.
Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al. The provisional pediatric rheumatology international trial organization/American College of Rheumatology/European league against rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum. 2008;59:4–13.
Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 2003;49:7–15.
Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology. 2009;48:134–9.
Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The childhood myositis assessment scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum. 1999;42:2213–9.
Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004;50:2281–90.
Ruperto N, Pistorio A, Ravelli A, et al. Criteria to define response to therapy in paediatric rheumatic diseases. Eur J Clin Pharmacol. 2011;67(Suppl 1):125–31.
•• Rider LG, Aggarwal R, Pistorio A, et al. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017;76:782–91. This report presents the new response criteria for JDM, with thresholds for minimal, moderate and major improvement.
De Latour H, Taylor WJ, Adebajo A, et al. Development of preliminary remission criteria for gout using Delphi and 1000Minds consensus exercises. Arthritis Care Res (Hoboken). 2016;68:667–72.
Consolaro A, Ravelli A. It is worth including assessment of disease activity state in juvenile arthritis clinical trials. Arthritis Care Res. 2013;65(8):1207–10.
Pincus T, Sokka T, Kavanaugh A. Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for “near remission” of DAS or single measures. Clin Exp Rheumatol. 2004;(Suppl 35):S50–6.
Dougados M. It’s good to feel better but it’s better to feel good [editorial]. J Rheumatol. 2005;32:1–2.
Kim S, El-Hallak M, Dedeoglu F, et al. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60:1825–30.
Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis. 2013;72:686–93.
• Almeida B, Campanilho-Marques R, Arnold K, et al. Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated. Arthritis Rheumatol. 2015;67:2495–502. This study highlights the potential shortcomings of the definition of clinically inactive disease in JDM patients with active skin disease.
Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658–66.
Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis. Defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012;64:2366–74.
Consolaro A, Ruperto N, Bracciolini G, Frisina A, Gallo MC, Pistorio A, et al. Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis. 2014;73:1380–3.
Consolaro A, Negro G, Gallo MC, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res (Hoboken). 2014;66:1703–9.
Rosina S, Consolaro A, van Dijkhuizen P, et al. Development and validation of a composite disease activity score for juvenile dermatomyositis [abstract]. In: 23rd Paediatric rheumatology European society congress; 28th Sept - 1st Oct 2016; genoa, Italy. Pediatric Rheumatology. 2017;15(Suppl 1):P358.
Magni-Manzoni S, Malattia C, Lanni S, Ravelli A. Advances and challenges in imaging in juvenile idiopathic arthritis. Nat Rev Rheumatol. 2012;8:329–36.
Davis WR, Halls JE, Offiah AC, Pilkington C, Owens CM, Rosendahl K. Assessment of active inflammation in juvenile dermatomyositis: a novel magnetic resonance imaging-based scoring system. Rheumatology. 2011;50:2237–44.
Castro TC, Lederman H, Terreri MT, Caldana WI, Zanoteli E, Hilário MOE. Whole-body magnetic resonance imaging in the assessment of muscular involvement in juvenile dermatomyositis/polymyositis patients. Scand J Rheumatol. 2014;43:329–33.
Malattia C, Damasio MB, Madeo A, Pistorio A, Providenti A, Pederzoli S, et al. Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Ann Rheum Dis. 2014;73:1083–90.
Habers GE, Van Brussel M, Bhansing KJ, et al. Quantitative muscle ultrasonography in the follow-up of juvenile dermatomyositis. Muscle Nerve. 2015;52:540–6.
Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, et al. The Cutaneous Assessment Tool (CAT): development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford). 2007;46:1606–11.
Huber AM, Lachenbruch PA, Dugan EM, Miller FW, Rider LG, For the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. For the juvenile dermatomyositis disease activity collaborative study group. Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: results using abbreviated formats. Arthritis Rheum. 2008;59:352–6.
Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies: development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford). 2004;43:49–54.
Klein RQ, Bangert CA, Costner M, Connolly MK, Tanikawa A, Okawa J, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol. 2008;159:887–94.
• Campanilho-Marques R, Almeida B, Claire D, et al. Comparison of the utility and validity of three scoring tools to measure skin involvement in patients with juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2016;68:1514–21. An analysis of the advantages and limitations of the most popular skin tools for JDM.
Lega JC, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev. 2014;13:883–91.
Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009;48:607–12.
Tansley S, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther. 2013;15:211.
Consolaro A, Varnier GC, Martini A, Ravelli A. Advances in biomarkers for paediatric rheumatic diseases. Nat Rev Rheumatology. 2015;11:265–75.
Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014;66:740–9.
• Deakin CT, Yasin SA, Simou S, et al. Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. Arthritis Rheumatol. 2016;68:2806–16. A demonstration of the potential prognostic role of severity of histopathologic findings on muscle biopsy and presence of myositis-specific autoantibodies.
Varnier GC, Rosina S, Ferrari C, Pistorio A, Consolaro A, Bovis F, et al. Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care. Arthritis Care Res (Hoboken). 2017. https://doi.org/10.1002/acr.23491
Berard R, Laxer RM. Improving the quality of care in children with juvenile idiopathic arthritis: a step in the right direction. J Rheumatol. 2011;38:789–90.
Filocamo G, Consolaro A, Ferrari C, Ravelli A. Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. Clin Exp Rheumatol. 2013;31:964–8.
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
This article is part of the Topical Collection on Inflammatory Muscle Disease
About this article
Cite this article
Rosina, S., Varnier, G.C., Mazzoni, M. et al. Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis. Curr Rheumatol Rep 20, 29 (2018). https://doi.org/10.1007/s11926-018-0734-4
- Juvenile dermatomyositis
- Idiopathic inflammatory myopathies
- Outcome measures
- Randomized clinical trials
- Disease remission